Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease

Carles Gaig1, Yaroslau Compta2, Anna Heidbreder2

  • 1From the Neuroimmunology Program (C. Gaig, L.S., A.I., J.S.C., J.D., F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Department of Neurology (C. Gaig, Y. Compta, M.J.M., A.I., J.S., J.D.), Multidisciplinary Sleep Disorders Unit (C. Gaig, A.I., J.S.), and Parkinson's Disease & Movement Disorders Unit (Y. Compta, M.J.M.), Hospital Clinic, Barcelona, Spain; Department of Neurology, Division of Sleep Medicine and Neuromuscular Disorders (A.H.), University Hospital Muenster, Germany; Department of Neurology (A.H., B.H.), Medical University of Innsbruck, Austria; Department of Neurology (M.J.T., Y. Crijnen), Erasmus MC University Medical Center, Rotterdam, the Netherlands; Department of Neurology (J.L.), Ulm University, Germany; Neurology Department, Complejo Hospitalario de Navarra (M.E.E.), Navarra Institute for Health Research (IdiSNA), Pamplona; Neurology Department (J.C.G.-M.), Hospital Universitario de Basurto, Bilbao (formerly Department of Neurology, Hospital de Galdakao); Movement Disorders Center (P.N., N. Tambasco), Perugia General Hospital and University of Perugia, Italy; Department of Neurology and Neurorehabilitation (M.P.-O.), Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland; Department of Neurology (M.E.), Klinik Donaustadt, Karl-Landsteiner-Institut, Vienna; Division of Neuropathology and Neurochemistry (R.H.), Department of Neurology (S.M., E.B.-S.), Medical University of Vienna, Austria; Section Translational Neuroimmunology (C. Geis), Department of Neurology, Jena University Hospital, Germany; Department of Neurology 1 (M.H.), Neuromed Campus, Kepler Universitätsklinikum Linz; Department of Neurology with Stroke Unit and Acute Geriatrics (M.H.), Saint John of God Hospital Linz, Austria; Department of Neurology and Neurosciences (A.M.-T., A.M.-B.), Clínica Universidad de Navarra, Pamplona-Madrid; Department of Neurology (L.L., S.Q.), Hospital La Princesa, Madrid, Spain; Department of Neurology (G.U.H., N.M.), Hannover Medical School; Department of Neurology (F.S.) and Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center (F.S.T.), Ludwig-Maximilians-University, Munich, Germany; Department of Biomedical and NeuroMotor Sciences (DiBiNeM) (G.M.A., F.P.), Alma Mater Studiorum University of Bologna; IRCCS Istituto delle Scienze Neurologiche di Bologna (F.P.); Department of Biomedical, Metabolic and Neural Sciences (G.P.), University of Modena and Reggio Emilia, Modena; IRCCS (G.P.), Institute of Neurological Sciences of Bologna, Italy; Neurology Department (K.B.), Cruces University Hospital, Barakaldo, Spain; Department of Neurology (M.B.), Odense University Hospital, Denmark; Department of Neurology and Institute of Neurogenetics (N.B.), University of Lübeck, Germany; Department of Neurology (T.F.), Medical Clinic of Hospital Geral Cleriston Andrade, Feira de Santana, Brazil; Neurology Unit, Department of Medicine (C.F.N.), Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia; Department of Movement Disorders and Neurology (C. Giordana), CHU Nice, France; Department of Neurology (A.H.-S.M.), Hospital Universitario 12 de Octubre, Madrid, Spain; Department of Psychobiology (L.H.), Universidade Federal de São Paulo, Brazil; Clinical Neurosciences (K.K.), St Vincent's Hospital, Melbourne, Australia; Department of Neurology (H.L.), LKH Murtal, Standort Knittelfeld, Austria; Department of Neurology (T.M.), Fundación Jiménez Diaz, Madrid; Department of Neurology (C.M.), Hospital Universitari i Politècnic La Fe, Valencia; Department of Neurology (J.P.P.), Hospital de la Santa Creu i Sant Pau, Barcelona; Department of Neurology (I.P.), Hospital La Paz, Madrid, Spain; Department of Neurology (T.S.-H.), Medical University of Graz, Austria; Department of Neurology (C.S.), Mainz University Hospital, Mainz, Germany; Department of Neurology (M.M.S.), University of São Paulo Medical School, Brazil; Department of Neurology (N. Tellez), Hospital Clínico Universitario, Valladolid; Department of Neurology (J.V.-Á.), Hospital Universitario Rey Juan Carlos, Madrid, Spain; Department of Neurology (B.W.), Antwerp University Hospital and University of Antwerp, Belgium; and Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain. cgaig@clinic.cat francesc.graus@idibaps.org.

Neurology
|August 12, 2021
PubMed
Abstract

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
986
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.5K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
566
Positive Symptoms of Schizophrenia: Hallucinations and Delusions01:30

Positive Symptoms of Schizophrenia: Hallucinations and Delusions

Schizophrenia is a complex mental health disorder that can manifest with various positive symptoms, including thought, movement, and behavior disorders. These symptoms significantly disrupt cognitive and motor functions, leading to profound effects on an individual's ability to engage with the world.
Thought Disorders
Disorganized and unusual thought processes mark thought disorders in schizophrenia. One key feature is disorganized speech, where an individual's conversation includes...
246
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.2K